Lytix Biopharma is a clinical-stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. Lead compound LTX-315 provides access to antigens by using the patient’s own tumor as source of antigens and turns cold tumors hot. Local treatment with LTX-315 targets the first step in the cancer immunity cycle with a potential cornerstone position in immunotherapy.